Vivan Therapeutics

Vivan Therapeutics has developed a proprietary genomics-based drug screening technology that creates patient-specific fruit fly avatars to test thousands of drug combinations. Their Personal Discovery Process identifies effective personalized therapies—often novel combinations of approved or investigational drugs—for hard-to-treat cancers. The company’s TuMatch AI software rapidly matches tumor DNA profiles to optimal therapies, currently available for colorectal cancer. They have ongoing collaborations with academic centers such as the Icahn School of Medicine at Mount Sinai and Barts Cancer Institute. No published clinical trial results are available yet; the focus remains on individualized therapy selection and supporting biopharma R&D.